Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KARMA: Ketamine for Sedation in Mechanically Ventilated ICU Patients
NCT07590687Phase 3Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketamine in critical illness (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Number of days patients are alive and spent at home at 60 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
critical illness
Beyond the preview
Go deeper on NCT07590687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07590687.